The development of the PlexiQoL: A patient‐reported outcome measure for adults with neurofibromatosis type 1‐associated plexiform neurofibromas

A Heaney, J Wilburn, M Rouse… - … Genetics & Genomic …, 2020 - Wiley Online Library
A Heaney, J Wilburn, M Rouse, S Langmead, JO Blakeley, S Huson, SP McKenna
Molecular Genetics & Genomic Medicine, 2020Wiley Online Library
Background To develop and validate a patient‐reported outcome (PRO) measure of quality
of life (QoL), specific to patients with Neurofibromatosis Type 1 (NF1)‐associated plexiform
neurofibromas (pNFs), suitable for use in clinical efficacy trials. The study was conducted in
parallel in the UK and US. Methods Qualitative interviews were conducted with patients to
generate questionnaire content. Face and content validity of the draft scale was assessed by
cognitive debriefing interviews (CDIs). A postal validation survey was conducted to identify …
Background
To develop and validate a patient‐reported outcome (PRO) measure of quality of life (QoL), specific to patients with Neurofibromatosis Type 1 (NF1)‐associated plexiform neurofibromas (pNFs), suitable for use in clinical efficacy trials. The study was conducted in parallel in the UK and US.
Methods
Qualitative interviews were conducted with patients to generate questionnaire content. Face and content validity of the draft scale was assessed by cognitive debriefing interviews (CDIs). A postal validation survey was conducted to identify the final version of the questionnaire (the PlexiQoL), establish its unidimensionality, and assess its psychometric properties.
Results
Thematic analysis was performed on 42 interview transcripts. Thirty‐one CDIs revealed that patients found the draft scale to be comprehensible, relevant, and easy to complete. The postal validation survey was completed by 273 patients. Rasch analysis identified an 18‐item unidimensional scale that showed excellent internal consistency, reproducibility, and sensitivity to differences in patient‐perceived pNF severity, general health, and the use of pain medication.
Conclusions
The PlexiQoL is the first disease‐specific PRO assessing the ability of adults with NF‐1 associated pNFs to meet their basic human needs. Clinical trials are planned to assess the sensitivity to change of the PlexiQoL in people undergoing treatment for pNFs.
Wiley Online Library
以上显示的是最相近的搜索结果。 查看全部搜索结果